Evidence map›Paper›PMID 41858341›Full record

ArticleFrontiers in oncology2026

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status.

Marcia S Brose, Bhumsuk Keam, Jolanta Krajewska, Ana O Hoff, Fernanda Vaisman, Chia-Chi Lin, Erika Hitre, Daniel W Bowles, Bruce Robinson, Steven I Sherman and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Marcia S BroseDepartment of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Jefferson University, Philadelphia, PA, United States.
Bhumsuk KeamDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Jolanta KrajewskaDepartment of Nuclear Medicine and Endocrine Oncology, Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland.
Ana O HoffDepartment of Endocrinology, Instituto do Cancer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil.
Fernanda VaismanDepartment of Endocrinology, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
Chia-Chi LinDepartment of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Erika HitreDepartment of Medical Oncology, The Multidisciplinary Head and Neck Cancer Center, Országos Onkológiai Intézet, Budapest, Hungary.
Daniel W BowlesDivision of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Bruce RobinsonDepartment of Medicine, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia.
Steven I ShermanDepartment of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Nuttapong NgamphaiboonDepartment of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Xiang GuoDepartment of Translational Medicine and Bioinformatics, Exelixis, Inc., Alameda, CA, United States.
Andrew SimmonsDepartment of Translational Medicine and Bioinformatics, Exelixis, Inc., Alameda, CA, United States.
Denise WilliamsonDepartment of Biostatistics, Exelixis, Inc., Alameda, CA, United States.
Svetlana AndrianovaDepartment of Late Phase Clinical Development, Exelixis, Inc., Alameda, CA, United States.
Nicholas BerryDepartment of Medical Affairs, Exelixis, Inc., Alameda, CA, United States.
Jaume CapdevilaDepartment of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), IOB Quiron-Teknon, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cabozantinib is approved for previously treated radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) based on improved progression-free survival (PFS) versus placebo in the COSMIC-311 study. The Methods: In this exploratory analysis, outcomes by Results: BRAF status was available for 106 of 258 patients enrolled in COSMIC-311; of these, 74 had Conclusions: In this subgroup analysis of COSMIC-311, cabozantinib improved PFS and ORR versus placebo irrespective of

Indexed as

BRAFBRAFV600EcabozantinibCOSMIC-311PFSRAIR-DTCTKI

Identifiers

PMID41858341
PMCPMC12995636

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.